AU2013278001A1 - Itraconazole compositions and dosage forms, and methods of using the same - Google Patents

Itraconazole compositions and dosage forms, and methods of using the same Download PDF

Info

Publication number
AU2013278001A1
AU2013278001A1 AU2013278001A AU2013278001A AU2013278001A1 AU 2013278001 A1 AU2013278001 A1 AU 2013278001A1 AU 2013278001 A AU2013278001 A AU 2013278001A AU 2013278001 A AU2013278001 A AU 2013278001A AU 2013278001 A1 AU2013278001 A1 AU 2013278001A1
Authority
AU
Australia
Prior art keywords
composition
itraconazole
oral pharmaceutical
pharmaceutical composition
exhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013278001A
Other languages
English (en)
Inventor
David Hayes
Stefan Lukas
Stuart James MUDGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
Mayne Pharma International Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902624A external-priority patent/AU2012902624A0/en
Application filed by Mayne Pharma International Pty Ltd filed Critical Mayne Pharma International Pty Ltd
Priority to AU2013278001A priority Critical patent/AU2013278001A1/en
Publication of AU2013278001A1 publication Critical patent/AU2013278001A1/en
Priority to AU2018201298A priority patent/AU2018201298B2/en
Priority to AU2020217438A priority patent/AU2020217438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013278001A 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same Abandoned AU2013278001A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2013278001A AU2013278001A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same
AU2018201298A AU2018201298B2 (en) 2012-06-21 2018-02-22 Itraconazole compositions and dosage forms, and methods of using the same
AU2020217438A AU2020217438A1 (en) 2012-06-21 2020-08-14 Itraconazole compositions and dosage forms, and methods of using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012902624 2012-06-21
AU2012902624A AU2012902624A0 (en) 2012-06-21 Itraconazole formulations and uses
PCT/US2013/047135 WO2013192566A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same
AU2013278001A AU2013278001A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201298A Division AU2018201298B2 (en) 2012-06-21 2018-02-22 Itraconazole compositions and dosage forms, and methods of using the same

Publications (1)

Publication Number Publication Date
AU2013278001A1 true AU2013278001A1 (en) 2015-01-22

Family

ID=49769445

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013278001A Abandoned AU2013278001A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same
AU2018201298A Active AU2018201298B2 (en) 2012-06-21 2018-02-22 Itraconazole compositions and dosage forms, and methods of using the same
AU2020217438A Abandoned AU2020217438A1 (en) 2012-06-21 2020-08-14 Itraconazole compositions and dosage forms, and methods of using the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018201298A Active AU2018201298B2 (en) 2012-06-21 2018-02-22 Itraconazole compositions and dosage forms, and methods of using the same
AU2020217438A Abandoned AU2020217438A1 (en) 2012-06-21 2020-08-14 Itraconazole compositions and dosage forms, and methods of using the same

Country Status (11)

Country Link
US (7) US8921374B2 (https=)
EP (1) EP2863911A4 (https=)
JP (2) JP2015531749A (https=)
KR (3) KR20200065093A (https=)
CN (2) CN104507480A (https=)
AU (3) AU2013278001A1 (https=)
BR (1) BR112014031706A8 (https=)
CA (1) CA2876909C (https=)
HK (1) HK1207288A1 (https=)
MX (1) MX366829B (https=)
WO (1) WO2013192566A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014031706A8 (pt) 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US11390613B2 (en) 2017-08-20 2022-07-19 University Of Connecticut Azole analogues and methods of use thereof
AU2019277362A1 (en) * 2018-05-30 2021-01-21 Mayne Pharma International Pty Ltd Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
CN115768779A (zh) * 2020-05-07 2023-03-07 上海偕怡医药科技有限公司 伊曲康唑前药及其用途
WO2023007514A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy's Laboratories Limited Improved oral bioavailable pharmaceutical compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6254889B1 (en) 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE255883T1 (de) 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
DE69730241T2 (de) 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
CA2317106C (en) 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
KR100529766B1 (ko) * 2003-09-09 2005-11-17 한미약품 주식회사 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법
US20050058670A1 (en) 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
US8486456B2 (en) * 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20110262517A1 (en) * 2007-04-05 2011-10-27 The Johns Hopkins University Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors
BR112014031706A8 (pt) 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol

Also Published As

Publication number Publication date
US20140005205A1 (en) 2014-01-02
MX366829B (es) 2019-07-25
HK1207288A1 (en) 2016-01-29
US20160030582A1 (en) 2016-02-04
JP2018162304A (ja) 2018-10-18
CA2876909C (en) 2022-08-16
CN104507480A (zh) 2015-04-08
KR20200065093A (ko) 2020-06-08
EP2863911A1 (en) 2015-04-29
US10463740B2 (en) 2019-11-05
WO2013192566A1 (en) 2013-12-27
CA2876909A1 (en) 2013-12-27
US9272046B2 (en) 2016-03-01
JP6757367B2 (ja) 2020-09-16
US20190125879A1 (en) 2019-05-02
MX2015000179A (es) 2016-02-16
US20150099763A1 (en) 2015-04-09
US11638758B2 (en) 2023-05-02
KR20150043296A (ko) 2015-04-22
KR20210043721A (ko) 2021-04-21
US8921374B2 (en) 2014-12-30
US20210038728A1 (en) 2021-02-11
AU2018201298B2 (en) 2020-05-14
US20200138959A1 (en) 2020-05-07
EP2863911A4 (en) 2016-07-13
AU2018201298A1 (en) 2018-03-15
US9713642B2 (en) 2017-07-25
BR112014031706A8 (pt) 2021-10-19
AU2020217438A1 (en) 2020-09-03
US10806792B2 (en) 2020-10-20
US20170348421A1 (en) 2017-12-07
BR112014031706A2 (pt) 2017-06-27
JP2015531749A (ja) 2015-11-05
CN109674795A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
US11638758B2 (en) Itraconazole compositions and dosage forms, and methods of using the same
EP3323413B1 (en) Pharmaceutical composition containing celecoxib and tramadol
JP6191883B2 (ja) 制御放出製剤
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
AU2026202283A1 (en) Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
WO2024081948A1 (en) Combination for use in treating cancers
CN119546312A (zh) 用于治疗银屑病的包含a3腺苷受体激动剂的药物组合物
US20240024248A1 (en) Fast dissolving pharmaceutical compositions
WO2023007514A1 (en) Improved oral bioavailable pharmaceutical compositions
US20140341988A1 (en) Orally dispersible drug formulations
HK1233907A1 (en) Allisartan isoproxil solid dispersion and pharmaceutical composition thereof
BR112015022103B1 (pt) Composição farmacêutica para prevenir ou tratar uma doença cardiovascular e uma doença hiperlipidêmica, ou tratar sinergicamente hipertensão, e, método para preparar uma composição farmacêutica

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted